Closely-held US biotech firm Alzheon has presented new analyses of previous Phase III data for tramiprosate, an investigational amyloid anti-aggregation agent and the active molecule of prodrug ALZ-801, in an oral presentation at the 9th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego.
Alzheon also presented a poster on the Phase I clinical studies and bridging data for ALZ-801, an optimized prodrug of tramiprosate, that support the pivotal clinical program planned to begin in 2017, which will evaluate ALZ-801 as a potential disease-modifying treatment for APOE4/4 homozygous patients at the mild stage of Alzheimer’s disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze